Epigenetics. Stem cell. Hematology. Immunology. @UniofOxford, @MRC_WIMM, @MRC_MHU.

Oxford, England
Joined May 2011
Excited to share that my postdoctoral work is finally out @NatureCellBio, thanks to all the great people @Simona66274422 @SThongjuea I've been working with @UniofOxford @MRC_WIMM. What a journey! nature.com/articles/s41556-0…
6
15
5
64
13,240
FlowJoのライセンスをどうするべきか悩んでましたが、今はFloreadaという解析ツールがあるんですね。使った感触はかなりよい。しかも無料! floreada.io/analysis
5
102
1
567
39,227
Yiran Meng retweeted
Claude Code 正式进化为科研助理Claude-Scholar! 它解决了科研中最耗时的环节: 1.全自动文献综述:支持 Zotero 同步,帮你自动整理文献。 2.数据实验分析:直接处理真实统计数据并给出结果。 3.论文全流程支持:从写作、反驳意见(Rebuttal)到演示幻灯片一条龙搞定。 4.内置 Obsidian 知识库:让你的研究笔记自动系统化。 github.com/Galaxy-Dawn/claud…
18
72
1
277
15,176
Yiran Meng retweeted
Equips Claude with skills for scientific research workflows github.com/K-Dense-AI/claude…
9
97
3
738
60,602
Teaching a new course @Stanford this quarter on explainable AI, motivated by neuroscience. I have curated a paper list 4 pages long (link in comment). What are your favorite papers on explainable AI/mechanistic interpretability that I am missing? Please comment or DM. thanks!
49
233
6
1,745
119,330
On arXiv, there’s a 200+ page overview book on AI and LLMs available. Covers pretty much all the fundamentals.
13
212
5
1,371
138,549
We are excited to announce the release of the @enGenome_srl VarChat track for hg38 and hg19. This track uses AI to search papers for variants, providing information such as its gene, HGVS nomenclature, and dbSNP rsID. Learn more at genome.ucsc.edu/goldenPath/n….
2
44
2
129
15,947
Yiran Meng retweeted
1/🧵Excited to re-introduce Memento in (cell.com/cell/fulltext/S0092…), a scalable method for differential analysis of scRNA-seq data. It provides first-in-class performance in statistical power and calibration for comparing differences in mean, variability, and gene correlation.👇
3
61
2
273
35,723
💡Thinking of using scRNA-seq to design antibody panels for spatial or single-cell profiling? Happy to launch Cytomarker, an interactive web-app and new antibody screening strategy to design and validate custom panels 1/6
1
55
1
266
37,694
📣Excited to share our new study in @NatureMedicine that @KexinHuang5 , @marinkazitnik, and I have been working on for the last four years! TxGNN is a graph-based foundation model for zero- shot drug repurposing that can find therapies for diseases with zero treatment options.
5
41
2
297
35,345
Yiran Meng retweeted
The integration of #cancer #biomarkers has revolutionized cancer treatment, allowing remarkable advancements in cancer therapeutics & the prognosis of cancer patients. This review paints the road ahead. sciencedirect.com/science/ar…
4
120
250
26,715
Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab @NatureMedicine @GeneCollector @xrtGenomics nature.com/articles/s41591-0…
1
42
1
167
16,547
Coordinated, multicellular patterns of transcriptional variation that stratify patient cohorts are revealed by tensor decomposition go.nature.com/47ARizC
23
2
74
26,580
CellChat for systematic analysis of cell–cell communication from single-cell transcriptomics nature.com/articles/s41596-0…
1
67
296
27,719
The first and last review written in my postdoc days. I may have left academia, but it's always fun to talk about HSCs.🥸🥸
Epigenetic regulation of hematopoietic stem cell fate dlvr.it/TDCf6y
1
11
543
Long-read sequencing for 29 immune cell subsets (Transcriptomic Resource of Immune Cells using Long-read Sequencing, TRAILS) reveals disease-linked isoforms nature.com/articles/s41467-0…
47
176
32,003
Single-cell multi-ome regression models identify functional and disease-associated enhancers and enable chromatin potential analysis | Nature Genetics nature.com/articles/s41588-0… #Bioinformatics
5
12
1,349
Accurate and sensitive mutational signature analysis with MuSiCal | Nature Genetics nature.com/articles/s41588-0… #Bioinformatics
5
7
787
A neoadjuvant treatment regimen of anti-PD-L1 #immunotherapy followed by anti-PD-L1 + chemotherapy was well tolerated and led to pathologic response rate of 70% in patients with resectable #GastricCancer or GEJ adenocarcinoma @MyriamChalabi @NKI_nl nature.com/articles/s41591-0…
14
1
51
19,349
CAR-T cell manufacturing: Major process parameters and next-generation strategies. A new review by Melanie Ayala Ceja, Yvonne Y. Chen and colleagues @UCLA hubs.la/Q02gDYfy0 #Immunotherapy #CancerFocus #leukemia #lymphoma
2
6
1,709